Yes, investors here should keep an eye on the political threat to Medicare and Medicaid, since those are critical insurers in the event of FDA approval of blarcamesine and an ultimate source of a great deal of revenue for us in the U.S. Alzheimer's market.
I like most elderly on medicare pay for our meds. My supplemental prescription plan helps but I still pick up my portion. These plans are not cheap and on top of monthly medicare costs. I don't know anyone getting anything cheap.
Market Data 
Markets 
AI
